IPO Databook: Zenshine Pharmaceuticals (Nanjing) Group (HK) - Aug 2026

101 Views28 Aug 2026 10:06

SUMMARY

Zenshine Pharmaceuticals, founded in 2018, is a commercial-stage biopharmaceutical company developing therapeutics for viral infectious diseases, oncology, and inflammatory disorders. Its core product, sebaloxavir marboxil tablets, received NMPA approval.
Zenshine's core product, sebaloxavir marboxil tablets, was approved for adult influenza in July 2025 and adolescent influenza in June 2026.
The company reported a loss of RMB209,268 thousand in 2025 and net liabilities of RMB(1,105,421) thousand as of June 30, 2026.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream

IPO Databook: Zenshine Pharmaceuticals (Nanjing) Group (HK) - Aug 2026
28 Aug 2026